BRAF-V600 mutant solid tumors
C4 Therapeutics Inc. is focused on solid tumors</span driven by BRAF-V600 mutations, with clinical interest spanning melanoma, non-small cell lung cancer, colorectal cancer, and anaplastic thyroid carcinoma.
- Melanoma
- Non-small cell lung cancer
- Colorectal cancer
- Anaplastic thyroid carcinoma
The sponsor’s clinical activity centers on tumors with the BRAF-V600 alteration, reflecting interest in genetically defined oncology populations across multiple disease settings.
Targeted oncology therapy
Its research landscape includes targeted cancer therapy with CFT1946, evaluated both as monotherapy and in combination therapy for mutant solid tumors.
- CFT1946
- Monotherapy
- Combination therapy
- Antitumor activity
Clinical interest extends to pairing this agent with trametinib or cetuximab, indicating attention to molecularly guided treatment strategies in oncology.
Advanced disease after standard treatment
The sponsor studies patients with advanced solid tumors who have already received standard of care therapy, with emphasis on treatment-resistant disease in oncology practice.
- Previously treated disease
- Treatment-resistant solid tumors
- Oncology after standard therapy
This area highlights clinical interest in later-line cancer treatment settings where new targeted options are needed.
Safety and preliminary efficacy
Research activity includes assessment of safety, tolerability, and preliminary antitumor activity in oncology populations.
- Safety
- Tolerability
- Preliminary efficacy
- Antitumor response
These interests align with clinical evaluation of new cancer therapeutics in genetically selected patients across multiple tumor types.
